GILD Form 4: CFO Andrew Dickinson sells 2,500 shares under 10b5-1
Rhea-AI Filing Summary
Gilead Sciences (GILD) CFO Andrew D. Dickinson reported an open‑market sale of 2,500 shares of common stock at $118.08 on October 15, 2025. The filing notes the trade was made under a Rule 10b5-1 trading plan adopted on August 29, 2024.
Following the transaction, Dickinson beneficially owns 157,055 shares, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 2,500 shares ($295,200)
Net Sell
1 txn
Insider
Dickinson Andrew D
Role
Chief Financial Officer
Sold
2,500 shs ($295K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,500 | $118.08 | $295K |
Holdings After Transaction:
Common Stock — 157,055 shares (Direct)
Footnotes (1)
- [object Object]
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Gilead (GILD) disclose in this Form 4?
The CFO, Andrew D. Dickinson, sold 2,500 shares at $118.08 on October 15, 2025.
Was the GILD insider trade under a Rule 10b5-1 plan?
Yes. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
What was the price and size of the GILD insider sale?
He sold 2,500 shares at a price of $118.08 per share.
Who is the reporting person in the GILD Form 4?
The reporting person is Andrew D. Dickinson, Gilead’s Chief Financial Officer.